Ventas adds $3.0 billion to at-the-market stock sale program; 12 directors elected
Ventas amended its at-the-market stock sale agreement, making $3.0 billion of common stock available for issuance, excluding shares sold before the amendment. That capacity could add shares outstanding, though the filing does not say any shares have been sold under it. At its May 13, 2026 annual meeting, shareholders elected all 12 director nominees, approved executive pay in an advisory vote, and ratified KPMG LLP as auditor for 2026.
Key points
- Amendment No. 3, dated May 15, 2026, sets the aggregate gross sales price of common stock available under the sales agreement at $3,000,000,000.
- At the May 13, 2026 annual meeting, 444,592,209 shares, or 93.50%, were represented.
- Advisory say-on-pay vote: 392,256,709 votes for and 35,413,128 against; KPMG LLP ratified with 437,540,505 votes for.
- Peter J. Bulgarelli, Executive Vice President, Outpatient Medical & Research, retired May 1, 2026; his separation agreement provides a prorated 2026 bonus based on target performance.
The filing
Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 15, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.